Report Detail

Pharma & Healthcare Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Insights, Forecast to 2025

  • RnM2440414
  • |
  • 12 April, 2019
  • |
  • Global
  • |
  • 119 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in these regions.
This research report categorizes the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market by top players/brands, region, type and end user. This report also studies the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Astellas Pharmaceuticals
Actavis
Pfizer
GlaxoSmithKline
Salix Pharmaceuticals Ltd
AstraZenenca

Market size by Product
Preface
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
Market size by End User
Hospitals
Clinics
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Study Coverage

    • 1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Product
      • 1.4.2 Preface
      • 1.4.3 Eluxadoline
      • 1.4.4 Alosetron
      • 1.4.5 Rifaximin
      • 1.4.6 Loperamide
      • 1.4.7 Diphenoxylate + Atropine
      • 1.4.8 Dicyclomine and Hyoscyamine
    • 1.5 Market by End User
      • 1.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size
      • 2.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2014-2025
      • 2.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2014-2025
    • 2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Growth Rate by Regions
      • 2.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Regions
      • 2.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers
      • 3.1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers
      • 3.1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers
      • 3.2.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Manufacturers
    • 3.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Product
    • 4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Product
    • 4.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Countries
      • 6.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries
      • 6.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Product
    • 6.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by End User

    7 Europe

    • 7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Countries
      • 7.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries
      • 7.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Product
    • 7.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Countries
      • 8.1.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries
      • 8.1.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Product
    • 8.3 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Countries
      • 9.1.1 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries
      • 9.1.2 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Product
    • 9.3 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Countries
      • 10.1.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Product
    • 10.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by End User

    11 Company Profiles

    • 11.1 Astellas Pharmaceuticals
      • 11.1.1 Astellas Pharmaceuticals Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
      • 11.1.5 Astellas Pharmaceuticals Recent Development
    • 11.2 Actavis
      • 11.2.1 Actavis Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
      • 11.2.5 Actavis Recent Development
    • 11.3 Pfizer
      • 11.3.1 Pfizer Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
      • 11.3.5 Pfizer Recent Development
    • 11.4 GlaxoSmithKline
      • 11.4.1 GlaxoSmithKline Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
      • 11.4.5 GlaxoSmithKline Recent Development
    • 11.5 Salix Pharmaceuticals Ltd
      • 11.5.1 Salix Pharmaceuticals Ltd Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
      • 11.5.5 Salix Pharmaceuticals Ltd Recent Development
    • 11.6 AstraZenenca
      • 11.6.1 AstraZenenca Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
      • 11.6.5 AstraZenenca Recent Development

    12 Future Forecast

    • 12.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Regions
      • 12.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Product
      • 12.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by End User
    • 12.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast
    • 12.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast
    • 12.6 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast
    • 12.7 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast
    • 12.8 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Summary:
      Get latest Market Research Reports on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs . Industry analysis & Market Report on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is a syndicated market report, published as Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,088.80
      4,633.20
      6,177.60
      3,603.60
      5,405.40
      7,207.20
      590,031.00
      885,046.50
      1,180,062.00
      325,143.00
      487,714.50
      650,286.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report